230 related articles for article (PubMed ID: 23791696)
1. Dengue dynamics and vaccine cost-effectiveness in Brazil.
Durham DP; Ndeffo Mbah ML; Medlock J; Luz PM; Meyers LA; Paltiel AD; Galvani AP
Vaccine; 2013 Aug; 31(37):3957-61. PubMed ID: 23791696
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
Shim E
Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
[TBL] [Abstract][Full Text] [Related]
3. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines.
Shim E
Am J Trop Med Hyg; 2016 Nov; 95(5):1137-1147. PubMed ID: 27601519
[TBL] [Abstract][Full Text] [Related]
4. The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.
Shafie AA; Yeo HY; Coudeville L; Steinberg L; Gill BS; Jahis R; Amar-Singh Hss
Pharmacoeconomics; 2017 May; 35(5):575-589. PubMed ID: 28205150
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dengue vaccination in ten endemic countries.
Zeng W; Halasa-Rappel YA; Baurin N; Coudeville L; Shepard DS
Vaccine; 2018 Jan; 36(3):413-420. PubMed ID: 29229427
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore.
Carrasco LR; Lee LK; Lee VJ; Ooi EE; Shepard DS; Thein TL; Gan V; Cook AR; Lye D; Ng LC; Leo YS
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1426. PubMed ID: 22206028
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of health economic evaluation studies of dengue vaccines.
de Soárez PC; Silva AB; Randi BA; Azevedo LM; Novaes HMD; Sartori AMC
Vaccine; 2019 Apr; 37(17):2298-2310. PubMed ID: 30910406
[TBL] [Abstract][Full Text] [Related]
8. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
Flasche S; Jit M; Rodríguez-Barraquer I; Coudeville L; Recker M; Koelle K; Milne G; Hladish TJ; Perkins TA; Cummings DA; Dorigatti I; Laydon DJ; España G; Kelso J; Longini I; Lourenco J; Pearson CA; Reiner RC; Mier-Y-Terán-Romero L; Vannice K; Ferguson N
PLoS Med; 2016 Nov; 13(11):e1002181. PubMed ID: 27898668
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a potential Zika vaccine candidate: a case study for Colombia.
Shoukat A; Vilches T; Moghadas SM
BMC Med; 2018 Jul; 16(1):100. PubMed ID: 29966516
[TBL] [Abstract][Full Text] [Related]
10. Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.
España G; Yao Y; Anderson KB; Fitzpatrick MC; Smith DL; Morrison AC; Wilder-Smith A; Scott TW; Perkins TA
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007482. PubMed ID: 31260441
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model.
Shim E
PLoS One; 2017; 12(4):e0175020. PubMed ID: 28380060
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission.
Orellano PW; Reynoso JI; Stahl HC; Salomon OD
Vaccine; 2016 Jan; 34(5):616-621. PubMed ID: 26724542
[TBL] [Abstract][Full Text] [Related]
13. Economic value of dengue vaccine in Thailand.
Lee BY; Connor DL; Kitchen SB; Bacon KM; Shah M; Brown ST; Bailey RR; Laosiritaworn Y; Burke DS; Cummings DA
Am J Trop Med Hyg; 2011 May; 84(5):764-72. PubMed ID: 21540387
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of dengue vaccination in Puerto Rico.
España G; Leidner AJ; Waterman SH; Perkins TA
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009606. PubMed ID: 34310614
[TBL] [Abstract][Full Text] [Related]
15. Current issues in the economics of vaccination against dengue.
Tozan Y
Expert Rev Vaccines; 2016; 15(4):519-28. PubMed ID: 26642099
[TBL] [Abstract][Full Text] [Related]
16. Projected Impact of Dengue Vaccination in Yucatán, Mexico.
Hladish TJ; Pearson CA; Chao DL; Rojas DP; Recchia GL; Gómez-Dantés H; Halloran ME; Pulliam JR; Longini IM
PLoS Negl Trop Dis; 2016 May; 10(5):e0004661. PubMed ID: 27227883
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
18. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
Lee JS; Lourenço J; Gupta S; Farlow A
Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874
[TBL] [Abstract][Full Text] [Related]
19. Economic Evaluations of Dengue Vaccination in the Southeast Asia Region: Evidence From a Systematic Review.
Supadmi W; Suwantika AA; Perwitasari DA; Abdulah R
Value Health Reg Issues; 2019 May; 18():132-144. PubMed ID: 31082793
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
